Skip to main content


Generic name: lenalidomide
Treatment for: Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma, Follicular Lymphoma

FDA and Celgene Revlimid Briefing Documents for Advisory Committee Meeting Available Online

WASHINGTON, September 13, 2005 -- Celgene Corporation announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the ODAC meeting scheduled to review the Revlimid (lenalidomide) New Drug Application (NDA) seeking approval for Revlimid for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
The ODAC meeting is scheduled from 8:00 a.m. EDT to 12:30 p.m. EDT on Wednesday, September 14, 2005. The NDA for Revlimid is under FDA priority review with a PDUFA date of October 7, 2005.

Source: Celgene Corporation

Related articles

Revlimid (lenalidomide) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.